Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
In idiopathic Parkinson's disease massive cell death occurs in the dopamine-containing substantia nigra. A link between the vulnerability of nigral neurons and the prominent pigmentation of the substantia nigra, though long suspected, has not been proved. This possibility is supported by evidence that N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its metabolite MPP+, the latter of which causes destruction of nigral neurons, bind to neuromelanin. We have directly tested this hypothesis by a quantitative analysis of neuromelanin-pigmented neurons in control and parkinsonian midbrains. The findings demonstrate first that the dopamine-containing cell groups of the normal human midbrain differ markedly from each other in the percentage of neuromelanin-pigmented neurons they contain. Second, the estimated cell loss in these cell groups in Parkinson's disease is directly correlated (r = 0.97, P = 0.0057) with the percentage of neuromelanin-pigmented neurons normally present in them. Third, within each cell group in the Parkinson's brains, there is greater relative sparing of non-pigmented than of neuromelanin-pigmented neurons. This evidence suggests a selective vulnerability of the neuromelanin-pigmented subpopulation of dopamine-containing mesencephalic neurons in Parkinson's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The nigra’s neuromelanin derives from dopamine and occurs in autolysosomes rather than melanosomes (226).”
From Chemiexcitation: Mammalian Photochemistry in the Dark† (2023) · cites this paper as [226]
In the citing paper
“The concept of such a substantial loss of EC neurons before AD symptoms occur may be analogous to the observation that very substantial neuronal losses are present in the substantia nigra before extrapyramidal symptoms become apparent in Parkinson's disease (Hirsch et al., 1988).”
From Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease (1996) · cites this paper as Hirsch et al., 1988
In the citing paper
“very substantial neuronal losses are present in the substantia nigra before extrapyramidal symptoms become apparent in Parkinson's disease (Hirsch et al., 1988).”
From Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease (1996) · cites this paper as Hirsch et al., 1988
Citations
Cites
Dahlstroem, A., & Fuxé, K. (1964) · PubMed · Cited by 5,133
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Recent developments in Parkinson's disease
Fahn, S., Elton, R., MARSDEN, C. D., Calne, D. B., & Goldstein, M. (1986) · Raven Press eBooks · Cited by 2,306
Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., & Kopin, I. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4546 · Cited by 2,149
STEELE, J. C. (1964) · Archives of Neurology · doi:10.1001/archneur.1964.00460160003001 · Cited by 1,924
Recent Developments in Parkinson's Disease
Hurtig, H. I. (1987) · Neurology · doi:10.1212/wnl.37.5.893 · Cited by 1,920
Emson, P., Heffher, R. R., & Pearson, J. (1984) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198409000-00010 · Cited by 1,648
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., & Kopin, I. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90006-4 · Cited by 1,376
Gerfen, C., Herkenham, M., & Thibault, J. (1987) · The Journal of Neuroscience · doi:10.1523/jneurosci.07-12-03915.1987 · Cited by 803
Hirsch, E. C., Graybiel, A. M., Duyckaerts, C., & Javoy-Agid, F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.16.5976 · Cited by 554
Self-citation
Research works printed but not linked: 6
- Escourolle, R., De Recondo, J. & Gray, F. in Monoamines Noyaux gris cenlraux et syndromes de Parkinson (eds de Ajuriaguerra, J. & Gauthier, G.) 173–229 (Geneva, 1970).
- Marsden, C. D. J. Neural Trans. Suppl. 19, 121–141 (1983).
- Dahlström, A. & Fuxe, K. Acta physiol. scand. 62, (Suppl. 232) 1–55 (1964).
- Graybiel, A. M. & Ragsdale, C. W. Jr in Chemical Neuroanalomy (ed. Emson, P. C.) 427–504 (Raven, New York, 1983).
- Graham, D. G. Molec. Pharmacol. 14, 633–643 (1978).
- Lindquist, N. G. Acta radiol. Suppl. 325, 1–92 (1973).
Cited by
Items 101–200 of 1,000
Iron and dopamine: a toxic couple
Hare, D. J., & Double, K. L. (2016) · Brain · doi:10.1093/brain/aww022 · Cited by 283
Crocker, S. J., Smith, P. D., Jackson-Lewis, V., Lamba, W. R., Hayley, S. P., Grimm, E., Callaghan, S. M., Slack, R. S., Melloni, E., Przedborski, S., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-10-04081.2003 · Cited by 274
“Hence, determinations of significance between the estimated proportion of immunopositive dopamine neurons in the PD subjects were compared with the control cases using a one-tailed Mann–Whitney rank sum test (Hirsch et al., 1988; Hartmann et al., 2001).”
MethodMonzani, E., Nicolis, S., Dell'Acqua, S., Capucciati, A., Bacchella, C., Zucca, F. A., Mosharov, E. V., Sulzer, D., Zecca, L., & Casella, L. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201811122 · Cited by 271
Hartmann, A., Troadec, J.-D., Hunot, S., Kikly, K., Faucheux, B. A., Mouatt-Prigent, A., Ruberg, M., Agid, Y., & Hirsch, E. C. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-07-02247.2001 · Cited by 270
“Within 2 hr of autopsy, tissue was dissected and processed as described previously (Hirsch et al., 1988).”
MethodInfluentialSelf-citationUnexpected expression of α- and β-globin in mesencephalic dopaminergic neurons and glial cells
Biagioli, M., Pinto, M., Cesselli, D., Zaninello, M., Lazarevic, D., Roncaglia, P., Simone, R., Vlachouli, C., Plessy, C., Bertin, N., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813216106 · Cited by 266
“Their selective degeneration leads to Parkinson’s disease (PD), and the loss of DA synapses in the striatum is believed to be primary cause for the disruption of the ability to control movements (1).”
BackgroundLotharius, J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.20.2395 · Cited by 269
The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease
Ilijic, E., Guzman, J. N., & Surmeier, D. J. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.04.007 · Cited by 259
Zhang, W., Phillips, K., Wielgus, A. R., Liu, J., Albertini, A., Zucca, F. A., Faust, R., Qian, S. Y., Miller, D. S., Chignell, C. F., et al. (2011) · Neurotoxicity Research · doi:10.1007/s12640-009-9140-z · Cited by 257
“SN pars compacta dopaminergic neurons containing neuromelanin (NM) degenerate to a greater extend in PD than dopaminergic neurons not containing NM (Hirsch et al. 1988) and free extracellular NM and microgliosis are”
Neurodegenerative Diseases – Is Metabolic Deficiency the Root Cause?
Muddapu, V. R., Dharshini, S. A. P., Chakravarthy, V. S., & Gromiha, M. M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00213 · Cited by 251
“However, dopaminergic neurons, which are abundantly present in other regions, such as ventral tegmental area (VTA) and olfactory bulb, are affected to much lesser extent (Hirsch et al., 1988; German et al., 1989, 1992; Dauer and Przedborski, 2003; Pacelli et al., 2015).”
BackgroundNeuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain
Cassidy, C. M., Zucca, F. A., Girgis, R. R., Baker, S. C., Weinstein, J. J., Sharp, M. E., Bellei, C., Valmadre, A., Vanegas, N., Kegeles, L. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1807983116 · Cited by 244
“NM-MRI signal is reliably decreased in the SN of patients with PD (8, 10, 12–15), consistent with the degeneration of NM-positive SN dopamine cells (16) and with the decrease in NM concentration in postmortem SN tissue of PD patients compared with age-matched controls (17).”
BackgroundResultCopper pathology in vulnerable brain regions in Parkinson's disease
Davies, K. M., Bohic, S., Carmona, A., Ortega, R., Cottam, V., Hare, D. J., Finberg, J. P. M., Reyes, S., Halliday, G. M., Mercer, J. F. B., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.09.034 · Cited by 244
“, 2008), an intracellular pigment found in vulnerable regions of the PD brain (Hirsch et al., 1988).”
BackgroundNeuromelanin of the Human Substantia Nigra: An Update
Zucca, F. A., Basso, E., Cupaioli, F. A., Ferrari, E., Sulzer, D., Casella, L., & Zecca, L. (2014) · Neurotoxicity Research · doi:10.1007/s12640-013-9435-y · Cited by 243
Zecca, L., Casella, L., Albertini, A., Bellei, C., Zucca, F. A., Engelen, M., Zadlo, A., Szewczyk, G., Zareba, M., & Sarna, T. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05541.x · Cited by 233
Motor and non-motor circuit disturbances in early Parkinson disease: which happens first?
Blesa, J., Foffani, G., Dehay, B., Bezard, E., & Obeso, J. A. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00542-9 · Cited by 232
Murer, M. G., Dziewczapolski, G., Menalled, L. B., García, M. C., Agid, Y., Gershanik, O., & Raisman‐Vozari, R. (1998) · Annals of Neurology · doi:10.1002/ana.410430504 · Cited by 232
“The experimental groups were constituted as follows: (1) for the 1993 set of rats: sham lesioned, receiving vehicle (n = 4) or levodopa (n = 4); moderately lesioned, vehicle (n = 9) or levodopa treated (n = 7); severely lesioned, vehicle (n = 5 ) or levodopa treated (n = 9) rats; (2) for the 1995 set of rats: sham les…”
BackgroundResultInfluentialSelf-citationAlterations of dopaminergic and noradrenergic innervations in motor cortex in parkinson's disease
Gaspar, P., Duyckaerts, C., Alvarez, C., Javoy‐Agid, F., & Berger, B. (1991) · Annals of Neurology · doi:10.1002/ana.410300308 · Cited by 231
Apathy following subthalamic stimulation in Parkinson disease: A dopamine responsive symptom
Czernecki, V., Schüpbach, M., Yaici, S., Lévy, R., Bardinet, E., Yelnik, J., Dubois, B., & Agid, Y. (2008) · Movement Disorders · doi:10.1002/mds.21949 · Cited by 230
Self-citationFaucheux, B. A., Martin, M., Beaumont, C., Hauw, J., Agid, Y., & Hirsch, E. C. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01923.x · Cited by 229
“Parkinson’s disease (PD) is characterized by neuronal degeneration that occurs in various regions of the brain, with the most severe neuronal loss taking place in the subpopulation of melanized dopaminergic neurones located in the substantia nigra pars compacta (SNpc; Hirsch et al., 1988).”
BackgroundSelf-citationSpecification of dopaminergic and serotonergic neurons in the vertebrate CNS
Hynes, M., & Rosenthal, A. (1999) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(99)80004-x · Cited by 229
Kastner, A., Hirsch, E. C., Lejeune, O., Javoy‐Agid, F., Rascol, O., & Agid, Y. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb08350.x · Cited by 228
Self-citationCooper, O., Hargus, G., Deleidi, M., Blak, A., Osborn, T., Marlow, E., Lee, K., Levy, A., Perez-Torres, E., Yow, A., et al. (2010) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2010.06.017 · Cited by 226
“The substantia nigra A9 type (SN-A9) DA neurons are relatively more vulnerable to significant degeneration than neighboring ventral tegmental area A10 type (VTA-A10) DA neurons (Damier et al., 1999; German et al., 1989; German et al., 1992; Hirsch et al., 1988).”
Metodiewa, D., & Kośka, C. (1999) · Neurotoxicity Research · doi:10.1007/bf03033290 · Cited by 226
Hynes, M., Poulsen, K., Tessier-Lavigne, M., & Rosenthal, A. (1995) · Cell · doi:10.1016/0092-8674(95)90454-9 · Cited by 226
Parkinson's disease: The syndrome, the pathogenesis and pathophysiology
Bartels, A. L., & Leenders, K. L. (2009) · Cortex · doi:10.1016/j.cortex.2008.11.010 · Cited by 225
α-Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease
Halliday, G. M., Ophof, A., Broe, M., Jensen, P. H., Kettle, E., Fedorow, H., Cartwright, M. I., Griffiths, F. M., Shepherd, C. E., & Double, K. L. (2005) · Brain · doi:10.1093/brain/awh584 · Cited by 219
“In humans, an obvious difference between A9 and other dopamineand non-dopamine-containing neurons in the brain is the increased pigmentation found in this cell group (Mann and Yates, 1983; Hirsch et al., 1988; Gibb, 1992; Kastner et al., 1992).”
BackgroundResultInfluentialBerg, D., Youdim, M. B. H., & Riederer, P. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0976-5 · Cited by 220
“As primarily neuromelanin-containing neurons degenerate in PD (Hirsch et al. 1988), with the largest pigmented neurons being preferentially lost, a cytotoxic effect of neuromelanin”
BackgroundBlood vessels change in the mesencephalon of patients with Parkinson's disease
Faucheux, B. A., Agid, Y., Hirsch, E. C., & Bonnet, A.-M. (1999) · The Lancet · doi:10.1016/s0140-6736(99)00641-8 · Cited by 218
Self-citationMolecular determinants of selective dopaminergic vulnerability in Parkinson’s disease: an update
Brichta, L., & Greengard, P. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00152 · Cited by 217
“…neurons in the SNpc and the VTA for a specific species may at least in part be due to interindividual differences between study subjects, but are most likely the result of different statistical methods that were applied to calculate the total number of DA neurons in the two midbrain nuclei.”
BackgroundMethodInfluentialFaucheux, B. A., Nillesse, N., Damier, P., Spik, G., Mouatt-Prigent, A., Pierce, A., Leveugle, B., Kubis, N., Hauw, J. J., & Agid, Y. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.21.9603 · Cited by 218
Self-citationOxidative stress and neurodegenerative disorders
Sun, A. Y., & Chen, Y.-M. (1998) · Journal of Biomedical Science · doi:10.1007/bf02255928 · Cited by 215
Parkinson’s disease as a result of aging
Rodriguez, M., Rodriguez‐Sabate, C., Morales, I., Sanchez, A., & Sabate, M. (2015) · Aging Cell · doi:10.1111/acel.12312 · Cited by 214
“PD showed a decrease in nigral pigmented neurons (Hirsch et al., 1988, 1989; Fearnley & Lees, 1991), which suggested that the selective degeneration of these cells could be a feature of this illness and that neuromelanin may be involved in this degeneration (Hirsch et al., 1988).”
BackgroundCompensatory mechanisms in experimental and human Parkinsonism: towards a dynamic approach
Bezard, E., & Gross, C. E. (1998) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00006-9 · Cited by 211
Innate Immunity and Neuroinflammation
Shastri, A., Bonifati, D. M., & Kishore, U. (2013) · Mediators of Inflammation · doi:10.1155/2013/342931 · Cited by 199
“In PD, these dopaminergic neurons are susceptible to degeneration [302] which is thought to be caused by activation of microglia by NM [303].”
BackgroundThe whole-brain pattern of magnetic susceptibility perturbations in Parkinson’s disease
Acosta-Cabronero, J., Cardenas-Blanco, A., Betts, M. J., Butryn, M., Valdes-Herrera, J. P., Galazky, I., & Nestor, P. J. (2017) · Brain · doi:10.1093/brain/aww278 · Cited by 200
Interaction of neuromelanin and iron in substantia nigra and other areas of human brain
Zecca, L., Shima, T., Stroppolo, A., Goj, C., Battiston, G. A., Gerbasi, R., Sarna, T., & Swartz, H. M. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00047-4 · Cited by 196
Smits, S. M., Ponnio, T., Conneely, O. M., Burbach, J. P. H., & Smidt, M. P. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02885.x · Cited by 194
The vulnerable ventral tegmental area in Parkinson’s disease
Alberico, S. L., Cassell, M. D., & Narayanan, N. S. (2015) · Basal Ganglia · doi:10.1016/j.baga.2015.06.001 · Cited by 192
“Additionally, of the studies providing patient symptoms, two stated that all cases exhibited tremor, rigidity, and akinesia/hypokinesia [21,22], while another reported that approximately half of the cases presented with these symptoms [24].”
BackgroundInfluentialNeuronal vulnerability in Parkinson’s disease
Hirsch, E. C., Faucheux, B., Damier, P., Mouatt-Prigent, A., & Agid, Y. (1997) · Journal of Neural Transmission. Supplementa · doi:10.1007/978-3-7091-6842-4_9 · Cited by 192
Self-citationKida, K., Yamada, M., Tokuda, K., Marutani, E., Kakinohana, M., Kaneki, M., & Ichinose, F. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3671 · Cited by 191
“It is characterized by a slow and progressive degeneration of dopaminergic neurons in the substantia nigra (10).”
BackgroundAnxiety in Parkinson’s disease: A critical review of experimental and clinical studies
Prediger, R. D. S., Matheus, F. C., Schwarzbold, M. L., Lima, M. M. S., & Vital, M. A. B. F. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.039 · Cited by 190
Zhang, F., Shi, J.-S., Zhou, H., Wilson, B., Hong, J.-S., & Gao, H.-M. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.064535 · Cited by 190
“It has been characterized by slow and progressive degeneration of dopamine (DA) neurons in the substantia nigra (SN) and a consequent severe decrease in DA levels in the striatum (Hirsch et al., 1988).”
BackgroundChemical anatomy of primate basal ganglia
Parent, A. (1995) · Progress in Neurobiology · doi:10.1016/0301-0082(95)00001-c · Cited by 187
Musgrove, R. E., Helwig, M., Bae, E.-J., Aboutalebi, H., Lee, S.-J., Ulusoy, A., & Di Monte, D. A. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127330 · Cited by 187
Lewy pathology and neurodegeneration in premotor Parkinson's disease
Del Tredici, K., & Braak, H. (2012) · Movement Disorders · doi:10.1002/mds.24921 · Cited by 185
Neuronal vulnerability, pathogenesis, and Parkinson's disease
Sulzer, D., & Surmeier, D. J. (2013) · Movement Disorders · doi:10.1002/mds.25187 · Cited by 184
Pathogenesis of nigral cell death in Parkinson's disease
Przedborski, S. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.10.012 · Cited by 183
“In addition, excess of cytosolic dopamine can stimulate the formation of neuromelanin [14], a dark intraneuronal pigment implicated in the greater susceptibility of nigral neurons to PD neurodegeneration [15].”
BackgroundIron-binding characteristics of neuromelanin of the human substantia nigra
Double, K. L., Gerlach, M., Schünemann, V., Trautwein, A. X., Zecca, L., Gallorini, M., Youdim, M. B. H., Riederer, P., & Ben-Shachar, D. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00293-4 · Cited by 181
Gaspar, P., Stepniewska, I., & Kaas, J. H. (1992) · Journal of Comparative Neurology · doi:10.1002/cne.903250102 · Cited by 182
Distribution of the dopamine innervation in the macaque and human thalamus
García-Cabezas, M. Á., Rico, B., Sánchez-González, M. Á., & Cavada, C. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2006.07.032 · Cited by 181
Dopamine transporter mRNA content in human substantia nigra decreases precipitously with age.
Bannon, M. J., Poosch, M. S., Xia, Y., Goebel, D. J., Cassin, B., & Kapatos, G. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.15.7095 · Cited by 180
The comparative biology of neuromelanin and lipofuscin in the human brain
Double, K. L., Dedov, V. N., Fedorow, H., Kettle, E., Halliday, G. M., Garner, B., & Brunk, U. T. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7581-9 · Cited by 179
Iron Storage within Dopamine Neurovesicles Revealed by Chemical Nano-Imaging
Ortega, R., Cloetens, P., Devès, G., Carmona, A., & Bohic, S. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000925 · Cited by 179
“Our results suggest that the elevation of iron concentration in the SNpc, and the concomitant loss of TH hydroxylase activity, may lead to a lack of irondopamine binding capability rendering the dopaminergic neurons Each series of images are representative of the entire cell population for each condition (control, 1mM…”
BackgroundInfluentialKulisevsky, J. (2000) · Drugs & Aging · doi:10.2165/00002512-200016050-00006 · Cited by 177
Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase
Xu, Y., Stokes, A. H., Roskoski, R., & Vrana, K. E. (1998) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19981201)54:5<691::aid-jnr14>3.0.co;2-f · Cited by 175
Filippi, A., Mahler, J., Schweitzer, J., & Driever, W. (2010) · Journal of Comparative Neurology · doi:10.1002/cne.22213 · Cited by 175
“DA and NA system dysfunctions are involved in a variety of psychiatric and neurological disorders, such as Parkinson’s disease and schizophrenia (Hirsch et al., 1988; Lang and Lozano, 1998).”
BackgroundAdenosine receptor antagonists for cognitive dysfunction: a review of animal studies
Takahashi, R. N. (2008) · Frontiers in Bioscience · doi:10.2741/2870 · Cited by 174
“These symptoms of PD result mainly from the progressive degeneration of dopamine neurons of the substantia nigra pars compacta (SNc) that project predominantly to the striatum (120), a”
BackgroundGreene, J. G., Dingledine, R., & Greenamyre, J. T. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.10.003 · Cited by 174
“…not all dopamine neurons are equally affected in human PD. Neurons in the ventral and lateral SN are much more susceptible than adjacent dopamine neurons in the ventral tegmental area (VTA) and other dopamine neurons in the hypothalamus (Fearnley and Lees, 1991; Hirsch et al., 1988; Rinne, 1993).”
BackgroundFarkas, L. M., Dünker, N., Roussa, E., Unsicker, K., & Krieglstein, K. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-12-05178.2003 · Cited by 174
“, Parkinson’s disease, schizophrenia, and drug addiction (Greenberg et al., 1974; Hirsch et al., 1988; Seeman et al., 1993).”
BackgroundAnimal models of Parkinson's disease: Limits and relevance to neuroprotection studies
Bezard, E., Yue, Z., Kirik, D., & Spillantini, M. G. (2013) · Movement Disorders · doi:10.1002/mds.25108 · Cited by 173
Lin, C.-H., Tsai, P.-I., Wu, R.-M., & Chien, C.-T. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1737-10.2010 · Cited by 168
“Additionally, neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), with its metabolite MPP (1-methyl-4-phenylpyridinium), preferentially binds to neuromelanin in the dopaminergic neurons, contributing to the susceptibility of these neurons in PD pathogenesis (Hirsch et al., 1988).”
BackgroundAlpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease
Oliveira, L. M. A., Gasser, T., Edwards, R., Zweckstetter, M., Melki, R., Stefanis, L., Lashuel, H. A., Sulzer, D., Vekrellis, K., Halliday, G. M., et al. (2021) · npj Parkinson's Disease · doi:10.1038/s41531-021-00203-9 · Cited by 168
Pham, A. H., Meng, S., Chu, Q. N., & Chan, D. C. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds311 · Cited by 166
“Likewise, SNc neurons in PD patients are more severely affected than the VTA population (26,27).”
BackgroundThe hidden sister of motor fluctuations in Parkinson's disease: A review on nonmotor fluctuations
Martínez‐Fernández, R., Schmitt, E., Martinez‐Martin, P., & Krack, P. (2016) · Movement Disorders · doi:10.1002/mds.26731 · Cited by 164
Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease
Milber, J. M., Noorigian, J. V., Morley, J. F., Petrovitch, H., White, L., Ross, G. W., & Duda, J. E. (2012) · Neurology · doi:10.1212/wnl.0b013e318278fe32 · Cited by 163
“If ILBD is a precursor to PD, some ILBD nigral neurons might display signs of dysfunction, such as diminished production of tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine synthesis and a validated marker for dopaminergic neuronal integrity.(11,13,15,16) Examination of cases of ILBD with early prenigra…”
BackgroundSalidroside ameliorates Parkinson's disease by inhibiting NLRP3-dependent pyroptosis
Zhang, X., Zhang, Y., Li, R., Zhu, L., Fu, B., & Yan, T. (2020) · Aging · doi:10.18632/aging.103215 · Cited by 163
“Therefore, neurotoxin MPTP has been one of the most extensive recognized drugs to induce PD model in vivo and in vitro [39, 40].”
BackgroundBraak, H., Rüb, U., Sandmann-Keil, D., Gai, W. P., de Vos, R. A. I., Jansen Steur, E. N. H., Arai, K., & Braak, E. (2000) · Acta Neuropathologica · doi:10.1007/s004010051150 · Cited by 163
Iron and Other Metals in Neuromelanin, Substantia Nigra, and Putamen of Human Brain
Zecca, L., Pietra, R., Goj, C., Mecacci, C., Radice, D., & Sabbioni, E. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.62031097.x · Cited by 163
“It has been recognized that neurons containing NM are more vulnerable than other nonmelanized dopamine neurons (Mann and Yates, 1983; Hirsch et al., 1988).”
BackgroundBiochemistry of Parkinson's disease 28 years later: A critical review
Agid, Y., Cervera, P., Hirsch, E., Javoy-Agid, F., Lehericy, S., Raisman, R., & Ruberg, M. (1989) · Movement Disorders · doi:10.1002/mds.870040514 · Cited by 163
Self-citationToll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease
Noelker, C., Morel, L., Lescot, T., Osterloh, A., Alvarez-Fischer, D., Breloer, M., Henze, C., Depboylu, C., Skrzydelski, D., Michel, P. P., et al. (2013) · Scientific Reports · doi:10.1038/srep01393 · Cited by 164
Prediger, R. D. S. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091459 · Cited by 160
Ma, S. Y., Röyttä, M., Rinne, J. O., Collan, Y., & Rinne, U. K. (1997) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(97)00100-7 · Cited by 160
Exosomes and stem cells in degenerative disease diagnosis and therapy
Chang, Y.-H., Wu, K.-C., Harn, H.-J., Lin, S.-Z., & Ding, D.-C. (2018) · Cell Transplantation · doi:10.1177/0963689717723636 · Cited by 159
Neuroprotective and Anti-inflammatory Activities of Ketogenic Diet on MPTP-induced Neurotoxicity
Yang, X., & Cheng, B. (2010) · Journal of Molecular Neuroscience · doi:10.1007/s12031-010-9336-y · Cited by 158
“It is characterized by the selective progressive loss of dopaminergic neurons in the substantia nigra (SN) and their projection fibers in the striatum subsequently (Hirsch et al. 1988; Hornykiewicz and Kish 1987).”
BackgroundPreservation of midbrain catecholaminergic neurons in very old human subjects
Kubis, N., Faucheux, B. A., Ransmayr, G., Damier, P., Duyckaerts, C., Henin, D., Forette, B., Le Charpentier, Y., Hauw, J.-J., Agid, Y., et al. (2000) · Brain · doi:10.1093/brain/123.2.366 · Cited by 157
“In order to reveal a possible common process during ageing and Parkinson’s disease neurodegeneration, catecholaminergic neurons of five anatomical regions of the brainstem (substantia nigra, central grey substance, ventral tegmental area, periand retrorubral area, and locus coeruleus) have been quantified using immuno…”
BackgroundMethodInfluentialSelf-citationOestreicher, E., Sengstock, G. J., Riederer, P., Olanow, C. W., Dunn, A. J., & Arendash, G. W. (1994) · Brain Research · doi:10.1016/0006-8993(94)90833-8 · Cited by 156
Engrailed protects mouse midbrain dopaminergic neurons against mitochondrial complex I insults
Alvarez-Fischer, D., Fuchs, J., Castagner, F., Stettler, O., Massiani-Beaudoin, O., Moya, K. L., Bouillot, C., Oertel, W. H., Lombès, A., Faigle, W., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2916 · Cited by 150
“Metabolic labeling of synaptoneurosomes and complex I, II and V immunocapture Synaptoneurosomes prepared from ventral midbrains of 4-week-old C57BL/6 mice by filtratio”
MethodOxidative Stress and Parkinson's Diseasea
OWEN, A. D., SCHAPIRA, A. H. V., JENNER, P., & MARSDEN, C. D. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb39064.x · Cited by 155
Freundlieb, N., François, C., Tandé, D., Oertel, W. H., Hirsch, E. C., & Höglinger, G. U. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4859-05.2006 · Cited by 154
“Furthermore , it is not known whether the dopaminergic innervation of the SVZ actually degenerates in Parkinson's disease, because not all dopaminergic cell populations are equally vulnerable to the disease process (Hirsch et al., 1988).”
BackgroundLin, W., Metzakopian, E., Mavromatakis, Y. E., Gao, N., Balaskas, N., Sasaki, H., Briscoe, J., Whitsett, J. A., Goulding, M., Kaestner, K. H., et al. (2009) · Developmental Biology · doi:10.1016/j.ydbio.2009.07.006 · Cited by 154
“These neurons have been extensively studied since loss of mdDA neurons is correlated with Parkinson's disease (Hirsch et al., 1988; Lang and Lozano, 1998).”
BackgroundComputational Dissection of Dopamine Motor and Motivational Functions in Humans
Bouc, R. L., Rigoux, L., Schmidt, L., Degos, B., Welter, M., Vidailhet, M., Daunizeau, J., & Pessiglione, M. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.3078-15.2016 · Cited by 181
“The dopaminergic loss occurs sooner and is stronger in the substantia nigra than in the ventral tegmental area (Hirsch et al., 1988; Damier et al., 1999).”
BackgroundVilaça-Faria, H., Salgado, A. J., & Teixeira, F. G. (2019) · Cells · doi:10.3390/cells8020118 · Cited by 152
“Still, DAn from the ventral tegmental area (VTA), retrorubal field (RRF), raphe nuclei (RN), and basal nucleus of Meynert (BNM) are also lost in PD, but to a lesser extent [13].”
BackgroundIs Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease?
Hartmann, A., Michel, P. P., Troadec, J., Mouatt‐Prigent, A., Faucheux, B. A., Ruberg, M., Agid, Y., & Hirsch, E. C. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00160.x · Cited by 153
Self-citationDose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP
Seniuk, N. A., Tatton, W. G., & Greenwood, C. E. (1990) · Brain Research · doi:10.1016/0006-8993(90)91055-l · Cited by 153
Sonnier, L., Le Pen, G., Hartmann, A., Bizot, J.-C., Trovero, F., Krebs, M.-O., & Prochiantz, A. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4583-06.2007 · Cited by 153
“Among these are the progressive loss of DA neurons and the differential loss between the VTA and the SN (Hirsch et al., 1988; Damier et al., 1999).”
BackgroundMethodContrast mechanisms associated with neuromelanin‐MRI
Trujillo, P., Summers, P. E., Ferrari, E., Zucca, F. A., Sturini, M., Mainardi, L. T., Cerutti, S., Smith, A. K., Smith, S. A., Zecca, L., et al. (2017) · Magnetic Resonance in Medicine · doi:10.1002/mrm.26584 · Cited by 150
Zucca, F. A., Vanna, R., Cupaioli, F. A., Bellei, C., De Palma, A., Di Silvestre, D., Mauri, P., Grassi, S., Prinetti, A., Casella, L., et al. (2018) · npj Parkinson's Disease · doi:10.1038/s41531-018-0050-8 · Cited by 151
“The formation of NM appears to provide a protective process,(3,10) but the amount of NM accumulated in neurons is related to their vulnerability in PD.(8,11,12) Due to its biochemical properties, NM has long been suggested as a critical factor underlying neuronal vulnerability in PD.”
BackgroundInfluentialSchildknecht, S., Gerding, H. R., Karreman, C., Drescher, M., Lashuel, H. A., Outeiro, T. F., Di Monte, D. A., & Leist, M. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12226 · Cited by 148
“Besides the formation of Lewy inclusions, another critical feature of PD is the degeneration of specific neuronal populations, including dopaminergic (DA) neurons of the substantia nigra (Hirsch et al. 1988).”
BackgroundMolecular basis for catecholaminergic neuron diversity
Grimm, J., Mueller, A., Hefti, F., & Rosenthal, A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405340101 · Cited by 150
Chapter 20 Neuropathological hallmarks of Alzheimer's and Parkinson's diseases
Braak, H., de Vos, R. A. I., Jansen, E. N. H., Bratzke, H., & Braak, E. (1998) · Progress in brain research · doi:10.1016/s0079-6123(08)64021-2 · Cited by 169
Ageing of substantia nigra in humans: cell loss may be compensated by hypertrophy
Cabello, C. R., Thune, J. J., Pakkenberg, H., & Pakkenberg, B. (2002) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2002.00393.x · Cited by 150
Prigent, A., Karlsson, J., Agid, Y., & Hirsch, É. C. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00100-5 · Cited by 161
Self-citationParkinson's disease: Alterations in iron and redox biology as a key to unlock therapeutic strategies
Ma, L., Gholam Azad, M., Dharmasivam, M., Richardson, V., Quinn, R. J., Feng, Y., Pountney, D. L., Tonissen, K. F., Mellick, G. D., Yanatori, I., et al. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101896 · Cited by 148
“It has been known for over 30 years that the neuromelanin-pigmented sub-population of dopamine-containing mesencephalic neurons in PD appears to be selectively vulnerable in this disease [475].”
BackgroundDuda, J., Pötschke, C., & Liss, B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13572 · Cited by 170
“…from (iron-catalyzed) dopamine oxidation, ROS production, metabolic stress, and from degeneration, while its neuronal release seems to have opposite effects on SN DA neurons, as it can propagate microglia activation, neuroinflammation, and neurodegeneration (Hirsch et al. 1988; Zucca et al. 2015).”
BackgroundNeuromelanin, aging, and neuronal vulnerability in Parkinson's disease
Vila, M. (2019) · Movement Disorders · doi:10.1002/mds.27776 · Cited by 168
“Consistent with this, inclusion-containing neurons in both humans(55) and hTyr-overexpressing rodents(43) often exhibit TH downregulation, which reflects neuronal dysfunction at early stages of neurodegeneration.(8) In addition, similar to hTyr-overexpressing rodents, the number of neuronal inclusions in PD brains at…”
BackgroundInfluentialJavoy-Agid, F., Hirsch, É. C., Dumas, S., Duyckaerts, C. J., Mallet, J. J., & Agid, Y. (1990) · Neuroscience · doi:10.1016/0306-4522(90)90389-l · Cited by 146
Self-citationThe probable relation between Toxoplasma gondii and Parkinson's disease
Miman, Ö., Küsbeci, Ö. Y., Aktepe, O. C., & Çetınkaya, Z. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.03.057 · Cited by 162
Cassano, T., Villani, R., Pace, L., Carbone, A., Bukke, V. N., Orkisz, S., Avolio, C., & Serviddio, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00124 · Cited by 144
Malkus, K. A., Tsika, E., & Ischiropoulos, H. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-24 · Cited by 142
“Alternatively, other studies have revealed a correlation in PD brains between cell loss and the presence of neuromelanin, which suggests that the neuromelanin-pigmented subpopulation of dopaminergic neurons are more vulnerable in disease [231].”
BackgroundNeuromelanin in Parkinson’s Disease: Tyrosine Hydroxylase and Tyrosinase
Nagatsu, T., Nakashima, A., Watanabe, H., Ito, S., & Wakamatsu, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084176 · Cited by 152
Metadata
- Authors
- Hirsch, E., Graybiel, A. M., & Agid, Y. A.
- Affiliations
- Massachusetts Institute of Technology (US)
- Inserm (FR)
- ORCID
- Graybiel, Ann M.
- Venue
- Nature
- Published
- 1988-07
- Volume
- 334
- Issue
- 6180
- Pages
- 345-348
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2054421268
- Semantic Scholar
- a3233ab8e74d927c8cdec03d6fc967cde7332aaf
- Cited by
- 1,301
- References
- 20
- Citations by year
- 2026: 21 · 2025: 33 · 2024: 29 · 2023: 35 · 2022: 47 · 2021: 51 · 2020: 48 · 2019: 45 · 2018: 37 · 2017: 34 · 2016: 48 · 2015: 49 · 2014: 47 · 2013: 43 · 2012: 50
- FWCI
- 23.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease, neuromelanin, dopaminergic neurons, substantia nigra, neuronal vulnerability, MPTP, MPP+, selective neuronal degeneration, midbrain, cell loss
- MeSH terms
- Acetylcholinesterase, Dopamine, Humans, Melanins, Nerve Degeneration, Neurons, Parkinson Disease, Pyridines, Pyridinium Compounds, Tyrosine 3-Monooxygenase, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 1-Methyl-4-phenylpyridinium
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.